<DOC>
	<DOCNO>NCT01522105</DOCNO>
	<brief_summary>5 Children &gt; 3months &lt; 16 year Gram-positive meningitis receive single dose daptomycin 24 hour first dose ceftriaxone . 4-8 hour daptomycin administration second lumbar puncture perform determine peak concentration daptomycin cerebrospinal fluid . In parallel peak trough level daptomycin measure plasma . The investigator anticipate daptomycin penetrates cerebrospinal fluid bactericidal concentration</brief_summary>
	<brief_title>Daptomycin Pediatric Patients With Bacterial Meningitis</brief_title>
	<detailed_description>Background Acute bacterial meningitis severe infection , lead persistent neurological deficit 50 % patient , despite optimal medical treatment . Although , incidence acute bacterial meningitis decline developed country since advent vaccine Haemophilus influenzae Streptococcus pneumoniae , yet true develop country . Also , impact serotype replacement invasive pneumococcal disease estimate date . Acute bacterial meningitis cause brain injury prominently cerebral cortex , inner ear hippocampus . In hippocampus , brain region functionally important learn memory , brain damage characterize apoptosis cell hippocampal dentate gyrus . Autopsy study demonstrate occurrence apoptosis neuron hippocampal dentate gyrus majority ( &gt; 75 % ) human autopsy case , die acute bacterial meningitis . Children particularly vulnerable form brain damage ongoing development neurological function high risk neurologic deficit bacterial meningitis adult . The 3 common pathogen childhood meningitis Streptococcus pneumoniae , Haemophilus influenzae Neisseria meningitidis . Streptococcus pneumoniae associate great risk fatal outcome persistent neurological deficit . In recent prospective study hearing loss common major sequelae half patient , follow cognitive deficit ( 40.0 % ) , seizures ( 21.2 % ) , motor deficit ( 21.2 % ) ; one third patient multiple defects.The pathogenesis brain damage meningitis drive host 's own inflammatory reaction invade pathogen subarachnoid space . This inflammatory reaction trigger release subcapsular bacterial component . Unfortunately , β-lactam antibiotic , current standard care bacterial meningitis , induce bacteriolysis lead brisk accumulation subcapsular bacterial component cerebrospinal fluid ( CSF ) , turn trigger over-shooting inflammatory reaction contribute brain damage . First evaluate 50 year ago , adjunctive corticosteroid still approve therapy minimize inflammatory reaction human . In child benefit combination therapy dexamethasone ceftriaxone proven reduction permanent hearing loss Haemophilus influenzae type b meningitis , pathogen today virtually eradicate region implement vaccination . Furthermore , beneficial effect dexamethasone administration meningitis challenge repeatedly . A recent prospective study two meta-analyses show conflict result consider benefit adjuvant corticosteroid treatment neurological outcome child acute bacterial meningitis . Furthermore , adjunctive corticosteroid treatment seem benefit patient acute bacterial meningitis develop country . Even worry result experimental meningitis , indicate dexamethasone might lead neuronal injury . Daptomycin ( Cubicin¨ , Novartis Pharma AG , Basel Switzerland ) cyclic lipopeptide antimicrobial agent active Gram-positive bacteria include strain resistant methicillin , vancomycin linezolid . It bind membrane Gram-positive bacteria cause rapid depolarization membrane potential lead bacterial cell death . Thereby , daptomycin exerts bactericidal , non-bacteriolytic effect cause release subcapsular bacterial component . Recently , proven experimental pneumococcal meningitis daptomycin lead substantially reduce inflammatory reaction compare ceftriaxone . Additionally , show compare ceftriaxone monotherapy , daptomycin plus ceftriaxone lower level pro-inflammatory mediator cerebrospinal fluid ( CSF ) reduce brain damage form hippocampal apoptosis hearing loss infant rat pneumococcal meningitis . Based experimental data summarize , appear reasonable assume use daptomycin , follow administration broad-spectrum antimicrobial agent child pneumococcal meningitis , Gram-positive meningitis , would lead reduced inflammatory response , ultimately , reduce incidence permanent neurological deficit . While establish pharmacokinetics ( PK ) daptomycin child age-dependent 6 , scarce data exist extent penetration daptomycin inflame CSF . Anecdotal evidence indicates human inflame meninges daptomycin penetrates CSF sufficient amount . This support animal study . There currently two pediatric study ongoing United States America . DAP-PEDS- 09-01 ass pharmacokinetics ( PK ) safety Daptomycin 18 child age 3-24 month Gram-positive bacterial infection . DAP-PEDS-07-03 assess efficacy safety multiple daptomycin dose 339 child age 2 - 17 year skin skin structure infection . Design dose study base previous finding two pediatric study involve 25 child age 2-17 year 12 child age 2-6 year . None study investigate daptomycin penetration CSF . As first step establish optimal dose recommendation daptomycin pediatric patient meningitis , present pharmacokinetic study attempt document adequate CSF penetration daptomycin child acute bacterial meningitis . Objective Characterize extent daptomycin penetrate CSF child acute bacterial meningitis . Because determination AUC CSF feasible , Cmax daptomycin CSF take surrogate marker Methods Children age 3 month 16 year acute bacterial meningitis recruit . After obtain baseline blood parameter include muscular enzyme , renal function , hepatic function , blood culture , lumbar puncture perform standard care therapy ceftriaxone 100mg/kg ( top dose 4g i.v . ) initiate . 24 hour hospitalisation single dose daptomycin age- dependent dosage , administer i.v . 15 min . shortly second dose ceftriaxone . 4-8 hour daptomycin administration second lumbar puncture perform obtain CSF sample measurement peak daptomycin level . Serum concentration daptomycin measure immediately i.v . administration , time lumbar puncture 24 hour daptomycin administration . Daptomycin therapy discontinue one dose , standard care antimicrobial therapy continue total 7 10 day .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Age &gt; 3 month &lt; 16 year Bacterial meningitis Written parental ( appropriate legal representative ) inform consent prior study inclusion Exclusion Criteria Gramnegative bacteria CSF Creatinine clearance &lt; 80ml/min/1.73m2 Creatinine phosphokinase level &gt; 2x upper age related norm Known allergy hypersensitivity daptomycin Known clinical significant cardiovascular , pulmonary , renal , hepatic , gastrointestinal , endocrine , hematologic , autoimmune disease , primary immunodeficiency Height weight 3rd 95th percentile History , current muscular disease Underlying neurological disease disruption blood brain barrier Epilepsy Muscular weakness , history peripheral neuropathy , GuillainBarré syndrome</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Central Nervous System Infections</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Daptomycin</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Therapeutic Use</keyword>
	<keyword>Pharmacologic Actions</keyword>
</DOC>